# Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -

> **NCT01093300** · PHASE4 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 264 (estimated)

## Conditions studied

- In-stent Restenosis Lesion

## Interventions

- **DEVICE:** Paclitaxel-eluting balloon catheter
- **DEVICE:** Everolimus-eluting stent

## Key facts

- **NCT ID:** NCT01093300
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01093300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01093300, "Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01093300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*